Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of HGP0918 and HGP0816 in Healthy Adults
NCT02554136Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin and omega-3-acid triglycerides in dyslipidemia and hypertriglyceridemia (6 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of HGP0918, Area Under the Curve to the Last Measurable Concentration (AUCt) of HGP0918 and 2 more. Started Jul 2015; status: completed.
02
Drugs
rosuvastatinomega-3-acid triglycerides
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NCT02554136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02554136.